ONL Therapeutics
Tuesday, February 27, 2024
Plymouth
Ophthalmology
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.
State
MI
Country
United States
Website
http://www.onltherapeutics.com
CEO/Top Company Official
David Esposito
Lead Product in Development
ONL1204
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
0
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}